Monotherapy with anti-PD-L1 and HM-3 demonstrated weaker anti-tumor effects, whereas treatment with B1451 and the combination of anti-PD-L1 and HM-3 exhibited strong anti-tumor efficacy (n=7, Figures 4B, C and online Supplementary Figure S1A). This evidence concerns the gene CD274 and neoplasm.